BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8261438)

  • 1. Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes.
    Ikarashi H; Fujita K; Takakuwa K; Kodama S; Tokunaga A; Takahashi T; Tanaka K
    Cancer Res; 1994 Jan; 54(1):190-6. PubMed ID: 8261438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes.
    Fujita K; Ikarashi H; Takakuwa K; Kodama S; Tokunaga A; Takahashi T; Tanaka K
    Clin Cancer Res; 1995 May; 1(5):501-7. PubMed ID: 9816009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer.
    Aoki Y; Takakuwa K; Kodama S; Tanaka K; Takahashi M; Tokunaga A; Takahashi T
    Cancer Res; 1991 Apr; 51(7):1934-9. PubMed ID: 2004379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study on immunotherapy of ovarian cancer with tumor infiltrating lymphocytes].
    Hua Z; Lu J; Li H
    Zhonghua Fu Chan Ke Za Zhi; 1996 Sep; 31(9):555-7. PubMed ID: 9275430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The comparison of biological characteristics between tumor-infiltrating lymphocytes and tumor-associated lymphocytes in ascites of epithelial ovarian carcinoma].
    Kang S; Shen K; Lang J
    Zhonghua Fu Chan Ke Za Zhi; 1998 Oct; 33(10):607-10. PubMed ID: 10806687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
    Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
    Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of immunocellular resistance to IL-2-activated lymphocytes within ovarian carcinoma cells.
    Papadopoulos AJ; Han X; Matossian-Rogers A; Raju KS
    Gynecol Oncol; 1995 Jun; 57(3):388-94. PubMed ID: 7774843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Social support, psychological distress, and natural killer cell activity in ovarian cancer.
    Lutgendorf SK; Sood AK; Anderson B; McGinn S; Maiseri H; Dao M; Sorosky JI; De Geest K; Ritchie J; Lubaroff DM
    J Clin Oncol; 2005 Oct; 23(28):7105-13. PubMed ID: 16192594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
    Zhang YX; Wang XY; Liu JB; Zhang SQ; Chen YR
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):973-6. PubMed ID: 18756970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
    Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients.
    Schöndorf T; Engel H; Kurbacher CM; Brenne U; Kolhagen H; Göhring UJ; Scharl A; Mallmann P
    J Soc Gynecol Investig; 1998; 5(2):102-7. PubMed ID: 9509389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells.
    Yang W; Feng J; Chang X; Fu T; Ye X; Zhang H; Li X; Wen H; Feng L; Tong C; Cui H
    Gynecol Oncol; 2007 Apr; 105(1):238-43. PubMed ID: 17383546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
    Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of perioperative cimetidine administration on peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: results of a randomized controlled clinical trial.
    Li Y; Yang GL; Yuan HY; Bai DJ; Wang K; Lin CR; Hu MB; Feng MH
    Hepatogastroenterology; 2005; 52(62):504-8. PubMed ID: 15816467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
    Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
    Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
    Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
    Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
    Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
    Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.